Phase I study of liposomal vincristine

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 697-705

  Gelmon, Karen A ^a   Tolcher, A ^a   Diab, A R ^a   Bally, M B ^a   Embree, L ^a   Hudon, N ^a   Dedhar, C ^a   Ayers, D ^a   Eisen, A ^a   Melosky, B ^a   Burge, C ^a   Logan, P ^a   Mayer, L D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; VINCRISTINE SULFATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032974761     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.697     Document Type: Article

References (25)

1. Mayer LD, Cullis PR, Bally MB: Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes, in Lassic D, Papahadjopoulos D (eds): Medical Applications of Liposomes. Amsterdam, The Netherlands, Elsevier Press, 1998, pp 231-256
2. Gabizon AA: Liposomal anthracyclines: Facing the clinical challenge. J Liposome Res 4:445-454, 1994
3. Martin FJ: Clinical pharmacology and antitumor efficacy of Doxil (pegylated liposomal doxorubicin): Sequus Pharmaceuticals, Inc., in Lassic D, Papahadjopoulos D (eds): Medical Applications of Liposomes. New York, NY, Elsevier Press, 1998, pp 635-688
4. Schmidt PG, Alder-Moore JP, Forssen EA, et al: Unilamellar liposomes for anticancer and antifungal therapy: Nexstar Pharmaceuticals, Inc., in Lassic D, Papahadjopoulos D (eds): Medical Applications of Liposomes. New York, NY, Elsevier Press, 1998, pp 703-732
5. Swenson CE, Freitag J, Janoff AS, The Liposome Company: Lipid-based pharmaceuticals in clinical development, in Lassic D, Papahadjopoulos D (eds): Medical Applications of Liposomes. New York, NY, Elsevier Press, 1998, pp 689-702
6. Boman NL, Bally BB, Cullis PR, et al: Encapsulation of vincristine in liposomes reduces its toxicity and improves its antitumor efficacy. J Liposome Res 5:523-541, 1995
7. Owellen RJ, Hartke CA, Dickerson RM, et al: Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 36:1499-1504, 1976
8. Owellen RJ, Owens AJ, Donigian DW: The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 47:685-689, 1972
9. Mayer LD, Masin D, Nayar R, et al: Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71:482-488, 1995
10. Jackson DV, Sethi VS, Spurr CL, et al: Intravenous vincristine infusion: Phase I trial. Cancer 48:2559-2564, 1981
11. Jackson DV, Paschold EH, Spurr CL, et al: Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 53:2601-2606, 1984
12. Haim N, Epelbaum R, Ben-Shahar M, et al: Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73:2515-2519, 1994
13. Mayer LD, Nayar R, Thies RL, et al: Identification of vesicle properties that enhance the antitumor activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33:17-24, 1993
14. Boman NL, Masin D, Mayer LD, et al: Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54:2830-2834, 1994
15. Webb MS, Harasym TO, Masin D, et al: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models. Br J Cancer 72:896-904, 1995
16. Dvorak HF, Nagy JA, Dvorak JT, et al: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95-109, 1988
17. Yuan F, Dellian M, Fukumura D, et al: Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756, 1995
18. Yuan F, Leunig M, Huang SK, et al: Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356, 1994
19. Kanter PM, Klaich GM, Bullard GA, et al: Liposome encapsulated vincristine: Preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5:579-590, 1994
20. Embree L, Gelmon K, Tolcher T, et al: Pharmacokinetic behaviour of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41:347-352, 1998
21. Embree L, Gelmon K, Tolcher A, et al: Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharmaceut Biomed Anal 16:675-687, 1997
22. 3H]-vincristine in man. Clin Pharmacol Ther 22:430-435, 1977
23. Rosenthal S, Kaufman S: Vincristine neurotoxicity. Ann Intern Med 80:733-737, 1974
24. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
25. Holland JF, Scharlau C, Gailani S, et al: Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Res 33:1258-1264, 1973